Thus, our in vitro and in vivo results suggest that anlotinib may be a strong PGP1 inhibitor candidate, which supports further investigation of combination chemotherapy that includes anlotinib plus conventional anticancer drugs in cancer patients with PGP1 overexpression. The gene discussed is CD44; the disease is cancer.